Anterior uveitis associated with latanoprost

Fechtner, Robert D.; Khouri, Albert S; Zimmerman, Thom J.; Bullock, John D.; Feldman, Robert M.; Kulkarni, Prasad S.; Michael, Andrew J.; Realini, Tony; Warwar, Ronald E.

doi:10.1016/s0002-9394(98)00071-3

Cited by 152 publications

(62 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 It has been shown that PG analogues can cause intraocular inflammation with rupture of the bloodaqueous and blood-retinal barriers in predisposed eyes. [8][9][10][11][12][13][14][15][16][17]21 The mechanisms associated with PG-induced intraocular inflammation have not been completely elucidated. It has been suggested that PGF 2a stimulates the release of PGE 2 , which in turn stimulates the release of arachidonic acid by activating phospholipase II.…”

Section: Discussionmentioning

confidence: 99%

“…[8][9][10][11][12][13][14][15][16][17] However, there is controversy regarding the effects of PG analogues on the BAB of phakic patients with no previous history of surgery or uveitis. [18][19][20][21][22][23][24] Furthermore, it has been reported that topical application of PG analogues may also reduce central corneal thickness (CCT), 25 which could influence IOP measurements by applanation tonometry. [26][27][28] While it is important to evaluate the ocular hypotensive efficacy of PG analogues, it is also necessary to determine their effects on the ocular surface and intraocular inflammatory reaction of phakic patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

Arcieri

Filho

Wakamatsu

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

Arcieri

Filho

Wakamatsu

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

“…Among this group of drugs, bimatoprost (Lumigan; Allergan, Irvine, Calif., USA) and travoprost (Travatan; Alcon, Fort Worth, Tex., USA) are two newer widely used intraocular-pressure-lowering agents in patients with glaucoma and ocular hypertension [22, 23]. Side effects associated with this group of drugs are reported as ocular hyperemia, increase in the length and thickness of the eyelashes, eyelid skin darkening, change in iris pigmentation, anterior uveitis and cystoid macular edema [21,24,25,26]. In this study, we compared the ocular surface side effects of bimatoprost and travoprost with regard to tearing response and conjunctival changes secondary to topical administration.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Alagöz

Bayer²,

Boran³

et al. 2008

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To compare the subjective symptoms, conjunctival hyperemia, tearing response and conjunctival cytological changes secondary to topical administration of bimatoprost and travoprost for 6 months. Methods: Newly diagnosed primary open-angle glaucoma patients were randomly prescribed bimatoprost (35 cases) or travoprost (42 cases). Two patients in each group were excluded because they did not appear at their appointments regularly. Thus, 33 and 40 patients completed the study in the bimatoprost and travoprost groups, respectively. Redness, itching, foreign-body sensation, pain and discomfort were assessed by a questionnaire, and patients were examined for conjunctival hyperemia. Schirmer’s I and break-up time tests were performed, and impression cytology of conjunctiva was evaluated. Results: Subjective symptoms were similar in both groups. The only subjective symptom that changed significantly was redness. The change in conjunctival hyperemia along the study period correlated with the patient-reported redness in both groups, being highest on day 30. Schirmer’s test I and break-up time did not change with time and were similar in both groups. The impression cytology grade increased with time in both groups with the only significant difference between groups on day 90 (higher in the bimatoprost group). Conclusion: We observed conjunctival hyperemia as the most common side effect of bimatoprost and travoprost. Tear film functions were not affected by these drugs while cytological alterations were.

show abstract

“…PGF2α may stimulate the release of PGE2, and hence activate phospholipase II, enhancing the production of inflammatory eicosanoids. 261 In support of an association between PGA and anterior uveitis, the inflammation appears to occur in the ipsilateral treated eye, 261 improve after cessation and recur after rechallenge. 256 Excessive doses may induce iritis.…”

mentioning

confidence: 98%

“…262 Affected subjects may have history of prior inflammation and/or incisional surgery. 261 A case report 256 documents an anterior uveitis rate as high as 4.9%, although no increase was found in PGA-treated subjects with anterior uveitis compared with those not on PGA treatment. 259 No increase in uveitic relapse rates were found when latanoprost was compared with FCDT (P = 0.21).…”

mentioning

confidence: 99%

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Lee

McCluskey

2010

OPTH

View full text Add to dashboard Cite

Prostaglandin analogs (PGA) are powerful topical ocular hypotensive agents available for the treatment of elevated intraocular pressure (IOP). Latanoprost 0.005% and travoprost 0.004% are prodrugs and analogs of prostaglandin F2α. Bimatoprost 0.03% is regarded as a prostamide, and debate continues as to whether it is a prodrug. The free acids of all 3 PGAs reduce IOP by enhancing uveoscleral and trabecular outflow via direct effects on ciliary muscle relaxation and remodeling of extracellular matrix. The vast majority of clinical trials demonstrate IOP-lowering superiority of latanoprost, bimatoprost and travoprost compared with timolol 0.5%, brimonidine 0.2%, or dorzolamide 2% monotherapy. Bimatoprost appears to be more efficacious in IOPlowering compared with latanoprost, with weighted mean difference in IOP reduction documented in one meta-analysis of 2.59% to 5.60% from 1-to 6-months study duration. PGAs reduce IOP further when used as adjunctive therapy. Fixed combinations of latanoprost, bimatoprost or travoprost formulated with timolol 0.5% and administered once daily are superior to monotherapy of its constituent parts. PGA have near absence of systemic side effects, although do have other commonly encountered ocular adverse effects. The adverse effects of PGA, and also those found more frequently with bimatoprost use include ocular hyperemia, eyelash growth, and peri-ocular pigmentary changes. Iris pigmentary change is unique to PGA treatment. Once daily administration and near absence of systemic side effects enhances tolerance and compliance. PGAs are often prescribed as first-line treatment for ocular hypertension and open-angle glaucoma.

show abstract

Anterior uveitis associated with latanoprost

Cited by 152 publications

References 12 publications

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

Comparison of Ocular Surface Side Effects of Topical Travoprost and Bimatoprost

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

Contact Info

Product

Resources

About